What are LRRK2 kinase inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LRRK2 kinase inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting LRRK2 (Leucine-rich repeat kinase 2)). 0 are currently marketed, with 2 more in clinical development.

LRRK2 kinase inhibitor

0 marketed 2 in Phase 2

This page covers all LRRK2 kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting LRRK2 (Leucine-rich repeat kinase 2), LRRK2 (leucine-rich repeat kinase 2).

Targets

LRRK2 (Leucine-rich repeat kinase 2) · LRRK2 (leucine-rich repeat kinase 2)

Phase 2 pipeline (2)

BIIB104 · Biogen · Neurology
BIIB104 is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neuronal cells.
DNL343 · Denali Therapeutics Inc. · Neurology
DNL343 is a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) that reduces pathological protein aggregation in neurodegeneration.

Patent intelligence

lrrk2 kinase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates